Incidence of Tumour Progression and Pseudoprogression in High-Grade Gliomas: a Systematic Review and Meta-Analysis

被引:105
|
作者
Abbasi, Abdul W. [1 ]
Westerlaan, Henriette E. [1 ]
Holtman, Gea A. [3 ]
Aden, Kamal M. [1 ]
van Laar, Peter Jan [1 ,2 ]
van der Hoorn, Anouk [1 ,2 ]
机构
[1] Univ Groningen, Univ Med Ctr Groningen, Dept Radiol, Hanzepl 1,30-001, NL-9700 RB Groningen, Netherlands
[2] Univ Groningen, Univ Med Ctr Groningen, Ctr Med Imaging North East Netherlands, Groningen, Netherlands
[3] Univ Groningen, Univ Med Ctr Groningen, Dept Gen Practice, Groningen, Netherlands
关键词
Treatment response assessment; Meta-analysis; Pseudoprogression; Incidence; High-grade gliomas; DIFFERENTIATING RADIATION NECROSIS; RECURRENT GLIOBLASTOMA-MULTIFORME; MAGNETIC-RESONANCE SPECTROSCOPY; APPARENT DIFFUSION-COEFFICIENT; CENTRAL-NERVOUS-SYSTEM; CEREBRAL BLOOD-VOLUME; TRUE PROGRESSION; MALIGNANT GLIOMA; PSEUDO-PROGRESSION; BRAIN-TUMOR;
D O I
10.1007/s00062-017-0584-x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background High-grade gliomas are the most common primary brain tumours. Pseudoprogression describes the false appearance of radiation-induced progression on MRI. A distinction should be made from true tumour progression to correctly plan treatment. However, there is wide variation of reported pseudoprogression. We thus aimed to establish the incidence of pseudoprogression and tumour progression in high-grade glioma patients with a systematic review and meta-analysis. Methods We searched PubMed, Embase and Web of Science on the incidence of pseudoprogression and tumour progression in adult high-grade glioma patients from 2005, the latest on 8 October 2014. Histology or imaging follow-up was used as reference standard. Extracted data included number of patients with worsening of imaging findings on T1 postcontrast or T2/FLAIR, pseudoprogression and tumour progression. Study quality was assessed. Heterogeneity was tested with I (2) . Pooling of the results was done with random models using Metaprop in STATA (StataCorp. Stata Statistical Software. College Station, TX: StataCorp LP). Results We identified 73 studies. MRI progression occurred in 2603 patients. Of these, 36% (95% confidence interval [CI] 33-40%) demonstrated pseudoprogression, 60% (95%CI 56-64%) tumour progression and unknown outcome was present in the remaining 4% of the patients (range 1-37%). Conclusion This meta-analysis demonstrated for the first time a notably high pooled incidence of pseudoprogression in patients with a form of progression across the available literature. This highlighted the full extent of the problem of the currently conventional MRI-based Response Assessment in Neuro-Oncology (RANO) criteria for treatment evaluation in high-grade gliomas. This underscores the need for more accurate treatment evaluation using advanced imaging to improve diagnostic accuracy and therapeutic approach.
引用
收藏
页码:401 / 411
页数:11
相关论文
共 50 条
  • [41] Comparison of fluorescein sodium, 5-ALA, and intraoperative MRI for resection of high-grade gliomas: A systematic review and network meta-analysis
    Naik, Anant
    Smith, Emily J.
    Barreau, Ariana
    Nyaeme, Mark
    Cramer, Samuel W.
    Najafali, Daniel
    Krist, David T.
    Arnold, Paul M.
    Hassaneen, Wael
    JOURNAL OF CLINICAL NEUROSCIENCE, 2022, 98 : 240 - 247
  • [42] The efficacy of topical imiquimod in high-grade cervical intraepithelial neoplasia: A systematic review and meta-analysis
    van de Sande, A. J. M.
    Kengsakul, M.
    Koeneman, M. M.
    Jozwiak, M.
    Gerestein, C. G.
    Kruse, A. J.
    van Esch, E. M. G.
    van Steenwijk, P. J. de Vos
    Muntinga, C. L. P.
    Bramer, W. M.
    van Doorn, H. C.
    van Kemenade, F. J.
    van Beekhuizen, H. J.
    INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 2024, 164 (01) : 66 - 74
  • [43] Efficacy and safety of pharmacotherapy for recurrent high-grade glioma: a systematic review and network meta-analysis
    Xu, Yanan
    Guan, Haijing
    Yu, Kefu
    Ji, Nan
    Zhao, Zhigang
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [44] Prophylactic anticonvulsant therapy in high-grade glioma: A systematic review and meta-analysis of longitudinal studies
    David Delgado-Lopez, Pedro
    Martin-Alonso, Javier
    NEUROCIRUGIA, 2020, 31 (06): : 268 - 278
  • [45] Survival outcomes and safety of carmustine wafers in the treatment of high-grade gliomas: a meta-analysis
    Chowdhary, Sajeel A.
    Ryken, Timothy
    Newton, Herbert B.
    JOURNAL OF NEURO-ONCOLOGY, 2015, 122 (02) : 367 - 382
  • [46] Survival outcomes and safety of carmustine wafers in the treatment of high-grade gliomas: a meta-analysis
    Sajeel A. Chowdhary
    Timothy Ryken
    Herbert B. Newton
    Journal of Neuro-Oncology, 2015, 122 : 367 - 382
  • [47] Influence of supratotal resection on overall survival and progression of tumor in gliomas grade 2 and 3: a systematic review and meta-analysis
    Falcao, Luciano
    Cerqueira, Gabriel Araujo
    Goncalves, Joao Pedro Fernandes
    de Andrade, Joao Felipe Tenisi
    Trocoli, Caio Passos de Azevedo Figueiredo
    Medrado-Nunes, Gabriel Souza
    Santos, Vanessa Emanuelle Cunha
    Pustilnik, Hugo Nunes
    Fontes, Jefferson Heber Marques
    dos Passos, George Santos
    NEUROSURGICAL REVIEW, 2025, 48 (01)
  • [48] Incidence and predictors of atrial fibrillation progression: A systematic review and meta-analysis
    Blum, Steffen
    Meyre, Pascal
    Aeschbacher, Stefanie
    Berger, Sebastian
    Auberson, Chloe
    Briel, Matthias
    Osswald, Stefan
    Conen, David
    HEART RHYTHM, 2019, 16 (04) : 502 - 510
  • [49] Tumour immune landscape of paediatric high-grade gliomas
    Ross, James L.
    Vega, Jose Velazquez
    Plant, Ashley
    MacDonald, Tobey J.
    Becher, Oren J.
    Hambardzumyan, Dolores
    BRAIN, 2021, 144 : 2594 - 2609
  • [50] Intrathecal chemotherapy for leptomeningeal disease in high-grade gliomas: a systematic review
    Singh, Eric
    Gurses, Muhammet Enes
    Costello, Meredith C.
    Lu, Victor M.
    Daggubati, Lekhaj
    Komotar, Ricardo J.
    Ivan, Michael E.
    Shah, Ashish H.
    JOURNAL OF NEURO-ONCOLOGY, 2024, 167 (01) : 39 - 47